- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Silexion Therapeutics Stock Surges 52% On Catalent Collaboration For Cancer Therapy | 1 | RTTNews | ||
| Mi | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| Mi | Silexion Therapeutics Corp: Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities | 7 | GlobeNewswire (USA) | ||
| 28.03. | Silexion erweitert Dual-Route-Strategie für KRAS-Krebstherapie | 1 | Investing.com Deutsch | ||
| 28.03. | Silexion advances dual-route strategy for KRAS cancer therapy | 2 | Investing.com | ||
| 28.03. | Silexion Therapeutics Corp: Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data | 142 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 28.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics GAAP EPS of -$26.36 | 5 | Seeking Alpha | ||
| 18.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 994 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 18.03. | Silexion Therapeutics Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 14.03. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer | 3 | Benzinga.com | ||
| 05.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models | 177 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 05.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 | 153 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 12.02. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 30.01. | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | 1.437 | AFX News | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| 29.01. | Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds | 15 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,136 | -0,98 % | Novavax Aktie: Optimistische Umsatzprognosen! | Die Novavax-Aktie gewinnt über 20% nach positiven Signalen der FDA zur COVID-19-Impfstoffzulassung. Weitere Studien sind jedoch erforderlich. Die Novavax-Aktie zeigt heute eine beeindruckende Rallye... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,179 | -1,76 % | Palatin Aktie: Gefährdete Stabilität! | Biotech-Firma Palatin kämpft gegen Börsenausschluss, während Orphan-Drug-Kandidat Hoffnung weckt. Kann die Pipeline die Finanzkrise abwenden? Die Uhr tickt für Palatin Technologies: Das Biotech-Unternehmen... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| VERASTEM | 6,400 | -3,03 % | Verastem Oncology to initiate trial for its targeted cancer therapy | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| QUANTUM-SI | 1,215 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,162 | -34,68 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,394 | 0,00 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| PSYENCE BIOMEDICAL | 0,460 | 0,00 % | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
| MINK THERAPEUTICS | 7,590 | 0,00 % | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock | ||
| SPRINGWORKS THERAPEUTICS | 44,990 | 0,00 % | Merck KGaA kurz vor Übernahme von Springworks für 3,5 Mrd USD | DJ Merck KGaA kurz vor Übernahme von Springworks für 3,5 Mrd USD
Von Ben Dummett und Lauren Thomas
DOW JONES--Die deutsche Merck KGaA steht laut mit der Angelegenheit vertrauten Personen kurz... ► Artikel lesen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,949 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.
